WINNIPEG, MB, Feb. 9, 2022
/CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH)
(OTC: MCUJF), a company focused on the development and
commercialization of pharmaceuticals and healthcare products for
patients and prescribers in the United
States market, is pleased to announce that it has launched
its national direct-to-consumer E-Commerce pharmacy platform –
www.marleydrug.com through its subsidiary, Marley
Drug® pharmacy.
For more than 100 million Americans who do not have prescription
drug coverage getting better and staying healthy can often depend
on access to affordable medications.
"Many hard-working Americans are now having to choose between
their medicine and other basic necessities," said Albert D. Friesen, PhD, Chief Executive Officer
of Medicure and Chair of its Board of Directors. "This is a choice
no American should ever have to make."
Marley Drug's new E-Commerce website is a platform where FDA
approved medications can be purchased at discount prices by
Americans for home delivery in all 50 States. Additionally, the
platform enables a client to store their medication and ordering
history, as well as that of their family, and reorder medications
or request refills all within the comfort of their home. The
platform focuses on ease-of-use, health and wellness resources and
a U.S. based pharmacy team dedicated to providing a pleasant
customer experience. Through the combination of technology, an
ever-expanding portfolio of medications, and superior customer
service, the E-commerce platform is designed to meet the evolving
needs of Americans and strengthen our existing lines of business
which include Medicure's primary care drug, ZYPITAMAG® and
future branded products.
In addition to the typical 30- and 90-day fill of medications,
the platform offers customers the ability to acquire extended
supply fills of 6 and 12 months. For chronic care medications, 6
and 12 month quantities could increase patient adherence and lead
to better management of medical conditions. Additional benefits
include fewer pharmacy visits, less frequent refills and overall
reduced cost. Marley Drug provides over 100 chronic care
medications at $37 for 6 months and
$70 for 12 months with free delivery
anywhere in the United States and
some territories. During the launch period, certain medications
will be available at just $2 per
month with free shipping for new customers.
"We look forward to growing the E-Commerce platform and
significantly increasing the affordability of health care for all
Americans and enhancing shareholder value", said Dr. Friesen.
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development
and commercialization of innovative and affordable therapeutics for
the U.S. market. Medicure's sales force markets to physicians and
other healthcare professionals and now with E-Commerce integration,
will be offering patients and providers direct online ordering and
home delivery. Our vision is to become a leading pharmaceutical
company within the U.S, offering a growing portfolio of products
that improve patients' lives. The present focus of the Company is
the marketing and distribution of AGGRASTAT® (tirofiban
hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in
the United States, where they are
sold through the Company's U.S. subsidiary, Medicure Pharma Inc.
Medicure also operates Marley Drug®, Inc. ("Marley Drug"), a
pharmacy located in North Carolina
that offers an Extended Supply drug program serving all 50 states,
Washington D.C. and most
territories, including Puerto
Rico. Marley Drug is committed to improving the health
status of its patients and the communities they serve while
reducing overall health care costs for employers and other health
care consumers. For more information visit www.marleydrug.com. To
learn more about The Extended Supply Generic Drug Program call
800.286.6781 or e-mail info@marleydrug.com. For more information on
Medicure please visit https://www.medicure.com/. For additional
information about AGGRASTAT®, refer to the full Prescribing
Information. For additional information about ZYPITAMAG®, refer to
the full Prescribing Information.
To be added to Medicure's e-mail list, please
visit:
https://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements contained in this press
release that are not statements of historical fact, including,
without limitation, statements containing the words "believes",
"may", "plans", "will", "estimates", "continues", "anticipates",
"intends", "expects" and similar expressions, may constitute
"forward-looking information" within the meaning of applicable
Canadian and U.S. federal securities laws (such forward-looking
information and forward-looking statements are hereinafter
collectively referred to as "forward-looking statements").
Forward-looking statements, include estimates, analysis and
opinions of management of the Company made in light of its
experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances.
Inherent in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's future product revenues, expected
results, including future revenue from the E-Commerce platform,
expected future growth in revenues, stage of development,
additional capital requirements, risks associated with the
completion and timing of clinical trials and obtaining regulatory
approval to market the Company's products, the ability to protect
its intellectual property, dependence upon collaborative partners,
changes in government regulation or regulatory approval processes,
and rapid technological change in the industry. Such statements are
based on a number of assumptions which may prove to be incorrect,
including, but not limited to, assumptions about: general business
and economic conditions; the impact of changes in Canadian-US
dollar and other foreign exchange rates on the Company's revenues,
costs and results; the timing of the receipt of regulatory and
governmental approvals for the Company's research and development
projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or
the availability of financing on reasonable terms; results of
current and future clinical trials; the uncertainties associated
with the acceptance and demand for new products and market
competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking
statements or the foregoing list of factors, other than as may be
required by applicable legislation. Additional discussion regarding
the risks and uncertainties relating to the Company and its
business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended December 31, 2020.
View original
content:https://www.prnewswire.com/news-releases/medicure-launches-e-commerce-pharmacy-platform--wwwmarleydrugcom-through-its-subsidiary-marley-drug-pharmacy-301478821.html
SOURCE Medicure Inc.
